GWAS Research of Lung Cancer in Tianjin

• Conditions: Primary Carcinoma; Non-small Cell Lung Cancer

• Registration Number: NCT01255059
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

Detailed Description

Eligibility criteria:

* nonsmoker

* female

* age between 35 and 80

* no other types of tumors history

* frequency-matched cases and controls on gender and age

Outcome measures:

* OR(odds ratio)

* RR(risk ratio)

* CI(confidence interval)

* SAS software

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-12-05
• Study First Submitted QC: 2010-12-05
• Study First Posted: 2010-12-07
• Status Verified: 2012-01
• Last Update Submitted: 2015-12-21
• Last Update Posted: 2015-12-22
• Primary Completion: 2016-11
• Study Completion: 2016-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

• Non-small cell lung cancer
• Age from 35 to 80 years old
• Female
• Non-smokers
• Frequency-matched on age and gender

Exclusion Criteria

• Previous medical history of cancer
• Previous radiotherapy
• Previous chemotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia	2011-12	A GWAS reported a novel association between the TP63 locus and risk of lung adenocarcinoma; however, this association did not achieve genome-wide significance among never-smoking males or females. We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China. Genetic variation in rs10937405 was associated with lung adenocarcinoma. Our findings provide strong evidence that genetic variation in TP63 is associated with risk of lung adenocarcinoma among non-smoking females.

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital; 🇨🇳 Tianjin, Tianjin, China